

Dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for Metastatic Melanoma

1. HOW DO YOU AS A PATIENT AND/OR CAREGIVER FEEL ABOUT THE pERC RECOMMENDATION FOR FUNDING OF DABRAFENIB (TAFINLAR) PLUS TRMETINIB (MEKINIST)?

75 % of patients originally interviewed were re-interviewed to ask if they were satisfied with the pERC recommendation above. All 75% of those interviewed were thrilled to see this decision made in a timely fashion and they all agreed that they are hoping once the final decision has been made that the provincial decision makers will ensure the same timely access. All patients interviewed were excited to know there are now options for those dealing with this type of cancer. They are hoping that these treatments will be available at all cancer clinics across the country as to not have to travel for treatment. All patients agreed that they are hoping the final decision will be made quickly as they feel time is of the essence when dealing with Melanoma.

All caregivers agreed, that they are glad that there is finally hope for their loved one and there are now options for Melanoma patients. Again their main concern is that these treatments become available at all cancer centres in a timely fashion.